Information  X 
Enter a valid email address

Xeros Tech Grp plc (XSG)

  Print      Mail a friend

Tuesday 21 January, 2020

Xeros Tech Grp plc

Block Listing Six Monthly Return

RNS Number : 4869A
Xeros Technology Group plc
21 January 2020
 

BLOCK LISTING SIX MONTHLY RETURN

 

 

The Company gives below the information required by Schedule 6 of the AIM Rules for Companies in connection with the Xeros Technology Group plc Enterprise Management Incentive Scheme and the Xeros Technology Group plc unapproved share option scheme.

 

 

Date: 21 January 2020

 

Name of applicant:

Xeros Technology Group Plc

Name of scheme:

Xeros Technology Group plc Enterprise Management Incentive Scheme ("EMI")

&

Xeros Technology Group plc unapproved share option scheme ("USOS")

Period of return:

From:

1 July 2019

To:

31 December 2019

Balance of unallotted securities under scheme(s) from previous return:

EMI: 904,338 ordinary shares of 0.15p each

USOS: 1,969,468 ordinary shares of 0.15p each

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

EMI: nil ordinary shares of 0.15p each

USOS: nil ordinary shares of 0.15p each

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

EMI: nil ordinary shares of 0.15p each

USOS: 15,384 ordinary shares of 0.15p each

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

EMI: 904,338 ordinary shares of 0.15p each

USOS: 1,954,084 ordinary shares of 0.15p each

Number and class of securities originally admitted and the date of admission:

EMI: 1,750,000 ordinary shares of 0.15p each on 27 January 2015

USOS: 313,166 ordinary shares of 0.15p each on 27 January 2015

 

 

Name of contact:

Paul Denney, Company Secretary

Telephone number of contact:

0114 2699656

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
BLRBBMITMTMTBMM

a d v e r t i s e m e n t